BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 21315483)

  • 1. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
    Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
    J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
    Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
    Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA; Strober BE
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
    Liu Y; Fan W; Chen H; Yu MX
    Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA; Symmons DP; Noyce PR; Ashcroft DM
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
    Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
    Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
    Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
    PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
    J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α and risk of infections: the experience in one center.
    Maruotti N; D'Onofrio F; Neve A; Santoro N; Corrado A; Cantatore FP
    Panminerva Med; 2014 Mar; 56(1):31-4. PubMed ID: 24637471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.